The role of islet amyloid polypeptide in type 2 diabetes

Canadian Journal of Diabetes

Volumn 29, Issue 1, 2005, Pages 39-47

  Marzban, Lucy ^a   Verchere, C Bruce ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Amylin; Amyloid; Beta cell; Islet amyloid polypeptide

Indexed keywords

AMYLIN; AMYLOID BETA PROTEIN; CONGO RED; GLUCAGON; HEPARAN SULFATE; INSULIN; SULFONIC ACID DERIVATIVE;

CELL DEATH; CYTOTOXICITY; DRUG INHIBITION; FIBER; GENE MUTATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW;

EID: 33646705618     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46:3-19.
2. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev. 1998;19:477-490.
3. Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes. 1994;43:1066-1084.
4. Polonsky KS. Lilly Lecture 1994. The β-cell in diabetes: from molecular genetics to clinical research. Diabetes. 1995;44:705-717.
5. DeFronzo RA. Lilly Lecture 1987. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988;37:667-687.
6. Porte D Jr. Banting Lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes. 1991;40:166-180.
7. Kahn BB. Type 2 diabetes: When insulin secretion fails to compensate for insulin resistance. Cell. 1998;92:593-596.
8. Turner RC. The UK Prospective Diabetes Study. A review. Diabetes Care. 1998;21(suppl 3):C35-C38.
9. Kahn SE. Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2001;86:4047-4058.
10. Deng S, Vatamaniuk M, Huang X, et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes. 2004;53:624-632.
11. Kloppel G, Lohr M, Habich K, et al. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res. 1985;4:110-125.
12. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102-110.
13. Furukawa H, Carroll KJ, Swift HH, Steiner DE. Long-term elevation of free fatty acids leads to delayed processing of proinsulin and prohormone convertases 2 and 3 in the pancreatic β-cell line MIN6. Diabetes. 1999;48:1395-1401.
14. Bjorklund A, Grill V. Enhancing effects of long-term elevated glucose and palmitate on stored and secreted proinsulin-to-insulin ratios in human pancreatic islets. Diabetes. 1999;48:1409-1414.
15. Lupi R, Dotta F, Marselli L, et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that β-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes. 2002;51:1437-1442.
16. Kahn SE, Andrikopoulos S, Verchere CB. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes. 1999;48:241-253.
17. Westermark P. Quantitative studies on amyloid in the islets of Langerhans. Ups J Med Sci. 1972;77:91-94.
18. Howard CF Jr. Insular amyloidosis and diabetes mellitus in Macaca nigra. Diabetes. 1978;27:357-364.
19. de Koning EJP, Bodkin NL, Hansen BC, Clark A. Diabetes mellitus in Macaca mulatta monkey is characterised by islet amyloidosis and reduction in beta-cell population. Diabetologia. 1993;36:378-384.
20. Johnson KH, O'Brien TD, Jordan K, Westermark P. Impaired glucose tolerance is associated with increased islet amyloid polypeptide (IAPP) immunoreactivity in pancreatic beta cells. Am J Pathol. 1989;135:245-250.
21. Westermark P. Amyloid and polypeptide hormones: what is their interrelationship? Amyloid. 1994;1:47-60.
22. Clark A, Wells CA, Buley ID, et al. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res. 1988;9:151-159.
23. Porte D Jr, Kahn SE. Beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes. 2001;50(suppl 1): S160-S163.
24. Verchere CB, D'Alessio DA, Palmiter RD, et al. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci U S A. 1996;93:3492-3496.
25. Couce M, Kane LA, O'Brien TD, et al. Treatment with growth hormone and dexamethasone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and beta-cell dysfunction. Diabetes. 1996;45:1094-1101.
26. Hoppener JW, Oosterwijk C, Nieuwenhuis MG, et al. Extensive islet amyloid formation is induced by development of type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia. 1999;42:427-434.
27. Soeller WC, Janson J, Hart SE, et al. Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide. Diabetes. 1998;47:743-750.
28. Lorenzo A, Razzaboni B, Weir GC, Yankner BA. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature. 1994;368:756-760.
29. Cooper GJ, Willis AC, Clark A, et al. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A. 1987;84:8628-8632.
30. Westermark P, Wernstedt C, Wilander E, et al. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci U S A. 1987;84:3881-3885.
31. Hoppener JW, Oosterwijk C, van Hulst KL, et al. Molecular physiology of the islet amyloid polypeptide (IAPP)/amylin gene in man, rat, and transgenic mice. J Cell Biochem. 1994;55(suppl):39-53.
32. Kahn SE, D'Alessio DA, Schwartz MW, et al. Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes. 1990;39:634-638.
33. Verchere CB, D'Alessio DA, Prigeon RL, et al. The constitutive secretory pathway is a major route for islet amyloid polypeptide secretion in neonatal but not adult rat islet cells. Diabetes. 2000;49:1477-1484.
34. Young A. Amylin's physiology and its role in diabetes. Curr Opin Endocrinol Diabetes. 1997;4:282-290.
35. Morley JE, Flood JF, Horowitz M, et al. Modulation of food intake by peripherally administered amylin. Am J Physiol. 1994;267(1 pt 2):R178-R184.
36. Morris MJ, Nguyen T. Does neuropeptide Y contribute to the anorectic action of amylin? Peptides. 2001;22:541-546.
37. Young AA, Gedulin B, Vine W, et al. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia. 1995;38:642-648.
38. Akesson B, Panagiotidis G, Westermark P, Lundquist I. Islet amyloid polypeptide inhibits glucagon release and exerts a dual action on insulin release from isolated islets. Regul Pept. 2003;111:55-60.
39. Gedulin BR, Rink TJ, Young AA. Dose-response for glucagonostatic effect of amylin in rats. Metabolism. 1997;46:67-70.
40. Degano P, Silvestre RA, Salas M, et al. Amylin inhibits glucose-induced insulin secretion in a dose-dependent manner. Study in the perfused rat pancreas. Regul Pept. 1993;43:91-96.
41. Leighton B, Cooper GJ. Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature. 1988;335:632-635.
42. Ahren B, Oosterwijk C, Lips CJ, Hoppener JW. Transgenic overexpression of human islet amyloid polypeptide inhibits insulin secretion and glucose elimination after gastric glucose gavage in mice. Diabetologia. 1998;41:1374-1380.
43. Gebre-Medhin S, Mulder H, Pekny M, et al. Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). Biochem Biophys Res Commun. 1998;250:271-277.
44. Hiddinga HJ, Eberhardt NL. Intracellular amyloidogenesis by human islet amyloid polypeptide induces apoptosis in COS-1 cells. Am J Pathol. 1999;154:1077-1088.
45. Hoppener JW, Nieuwenhuis MG, Vroom TM, et al. Role of islet amyloid in type 2 diabetes mellitus: consequence or cause? Mol Cell Endocrinol. 2002;197:205-212.
46. Clark A, Nilsson MR. Islet amyloid: a complication of islet dysfunction or an aetiological factor in type 2 diabetes? Diabetologia. 2004;47:157-169.
47. Rumora L, Hadzija M, Barisic K, et al. Amylin-induced cytotoxicity is associated with activation of caspase-3 and MAP kinases. Biol Chem. 2002;383:1751-1758.
48. Zhang S, Liu J, Dragunow M, Cooper GJ. Fibrillogenic amylin evokes islet beta-cell apoptosis through linked activation of a caspase cascade and JNK1. J Biol Chem. 2003;278:52810-52819.
49. Mirzabekov TA, Lin MC, Kagan BL. Pore formation by the cytotoxic islet amyloid peptide amylin. J Biol Chem. 1996;271:1988-1992.
50. Anguiano M, Nowak RJ, Lansbury PT Jr. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry. 2002;41:11338-11343.
51. Sanke T, Bell GI, Sample C, et al. An islet amyloid peptide is derived from an 89-amino acid precursor by proteolytic processing. J Biol Chem. 1988;263:17243-17246.
52. Badman MK, Shennan KI, Jermany JL, et al. Processing of pro-islet amyloid polypeptide (proIAPP) by the prohormone convertase PC2. FEBS Lett. 1996;378:227-231.
53. Higham CE, Hull RL, Lawrie L, et al. Processing of synthetic pro-islet amyloid polypeptide (proIAPP) 'amylin' by recombinant prohormone convertase enzymes, PC2 and PC3, in vitro. Eur J Biochem. 2000;267:4998-5004.
54. 2-terminal cleavage site. Diabetes. 2001;50:534-549.
55. Marzban L, Trigo-Gonzalez G, Zhu X, et al. Role of β-cell prohormone convertase (PC)1/3 in processing of pro-islet amyloid polypeptide. Diabetes. 2004;53:141-148.
56. Furuta M, Carroll R, Martin S, et al. Incomplete processing of proinsulin to insulin accompanied by elevation of des-31,32 proinsulin intermediates in islets of mice lacking active PC2. J Biol Chem. 1998;273:3431-3437.
57. Zhu X, Orci L, Carroll R, et al. Severe block in processing of proinsulin to insulin accompanied by elevation of des-64,65 proinsulin intermediates in islets of mice lacking prohormone convertase 1/3. Proc Natl Acad Sci U S A. 2002;99:10299-10304.
58. de Koning EJ, Morris ER, Hofhuis FM, et al. Intra- and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci U S A. 1994;91:8467-8471.
59. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A. 1995;92:4725-4727.
60. Vidal J, Verchere CB, Andrikopoulos S, et al. The effect of apolipoprotein E deficiency on islet amyloid deposition in human islet amyloid polypeptide transgenic mice. Diabetologia. 2003;46:71-79.
61. Park K, Verchere CB. Identification of a heparin binding domain in the N-terminal cleavage site of pro-islet amyloid polypeptide. Implications for islet amyloid formation. J Biol Chem. 2001;276:16611-16616.
62. Westermark P, Engstrom U, Johnson KH, et al. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A. 1990;87:5036-5040.
63. Jaikaran ET, Higham CE, Serpell LC, et al. Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis. J Mol Biol. 2001;308:515-525.
64. Nilsson MR, Raleigh DP. Analysis of amylin cleavage products provides new insights into the amyloidogenic region of human amylin. J Mol Biol. 1999;294:1375-1385.
65. Verchere CB, D'Alessio DA, Wang S, et al. Transgenic overproduction of islet amyloid polypeptide (amylin) is not sufficient for islet amyloid formation. Horm Metab Res. 1997;29:311-316.
66. Kahn SE, Halban PA. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes. 1997;46:1725-1732.
67. Westermark P, Eizirik DL, Pipeleers DG, et al. Rapid deposition of amyloid in human islets transplanted into nude mice. Diabetologia. 1995;38:543-549.
68. Hou X, Ling Z, Quartier E, et al. Prolonged exposure of pancreatic beta cells to raised glucose concentrations results in increased cellular content of islet amyloid polypeptide precursors. Diabetologia. 1999;42:188-194.
69. Westermark P, Engstrom U, Westermark GT, et al. Islet amyloid polypeptide (IAPP) and pro-IAPP immunoreactivity in human islets of Langerhans. Diabetes Res Clin Pract. 1989;7:219-226.
70. Sakagashira S, Sanke T, Hanabusa T, et al. Missense mutation of amylin gene (S20G) in Japanese NIDDM patients. Diabetes. 1996;45:1279-1281.
71. Seino S. S20G mutation of the amylin gene is associated with type II diabetes in Japanese. Study Group of Comprehensive Analysis of Genetic Factors in Diabetes Mellitus. Diabetologia. 2001;44:906-909.
72. Sakagashira S, Hiddinga HJ, Tateishi K, et al. S20G mutant amylin exhibits increased in vitro amyloidogenicity and increased intracellular cytotoxicity compared to wild-type amylin. Am J Pathol. 2000;157:2101-2109.
73. Novials A, Rojas I, Casamitjana R, et al. A novel mutation in islet amyloid polypeptide (IAPP) gene promoter is associated with type II diabetes mellitus. Diabetologia. 2001;44:1064-1065.
74. Cook JT, Patel PP, Clark A, et al. Non-linkage of the islet amyloid polypeptide gene with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1991;34:103-108.
75. Nishi M, Bell GI, Steiner DF. Islet amyloid polypeptide (amylin): no evidence of an abnormal precursor sequence in 25 type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1990;33:628-630.
76. Pildal J, Lajer M, Hansen SK, et al. Studies of variability in the islet amyloid polypeptide gene in relation to type 2 diabetes. Diabetic Med. 2003;20:491-494.
77. Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci U S A. 1994;91:12243-12247.
78. Scrocchi LA, Chen Y, Waschuk S, et al. Design of peptide-based inhibitors of human islet amyloid polypeptide fibrillogenesis. J Mol Biol. 2002;318:697-706.
79. Lin YM, Raffen R, Zhou Y, et al. Amyloid fibril formation in microwell plates for screening of inhibitors. Amyloid. 2001;8:182-193.
80. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979-982.
81. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173-177.
82. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982-985.
83. McLaurin J, Cecal R, Kierstead ME, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med. 2002;8:1263-1269.
84. Potter-Perigo S, Hull RL, Tsoi C, et al. Proteoglycans synthesized and secreted by pancreatic islet beta-cells bind amylin. Arch Biochem Biophys. 2003;413:182-190.
85. Kisilevsky R, Lemieux LJ, Fraser PE, et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med. 1995;1:143-148.